Takk for input @holmes, du kjenner selskapet langt bedre enn meg, og det høres fornuftig ut det du sier.
Beklager feilen mht uttalelsene over, de var ikke fra styreleder men fra Leif Ryd (som var en av grunnleggerne i firmaet?).
Avventer likevel finansieringsplanene før jeg hiver meg på her.
Synes dette er en veldig god analyse over hvorfor dette selskapet har lidd sånn på børsen.
Er finansieringen som holder meg på gjerdet og.
Bør komme deg inn. Det er noe stort i gjerde slik som kursen går nå.
Voldsomt hopp i kursen idag og! Er det noen som vet noe mer, eller der det bare en standard Pump & Dump før emisjon?
Kjenner jeg ble veldig usikker på denne nå, har brent meg før på selskaper med lav krigskasse.
Det som taler i mot emisjon for min del, er at de ikke har hatt stor suksess med de tidligere (ikke fulltegnet osv) så skulle kanskje tro de ser etter andre løsninger?
fk it. Hakon gir sin anbefaling. Han spanderer sikkert en ny bil på deg om det går galt 
Sykt at jeg klarte å tape på en trade her. Står utenfor nå. Solgte selvom jeg er super bullish fordi jeg trodde den skulle lenger ned først pga emi
DNB har kommentert Talus i EU og opprettholder sin fair value range på 1.8-4.8.
Det hjalp nok på å dytte kursen videre her.
Mitt råd i aksjer som man tror skal kortsiktig ned og vil selge, men som man er meget positivt langsiktig er å selge toppen 50%. Da er man fremdeles bra med i tilfelle man tar feil og aksjen fortsetter opp. Dette begynte jeg selv med etter å ha brent meg noen ganger…
Ja bra råd. Uansett ikke mye tap på traden, men bittert å miste oppgang når man egentlig har trua. Er et psykologisk mønster jeg ofte faller i at jeg avventer inngang for lenge
EPISURF
Episurf Medical uppdaterar om AI-baserad produktionsprocess (Cision)
2020-01-16 09:00
Episurf Medical (NASDAQ: EPIS B) uppdaterar om bolagets förmåga kring 3D-visualisering av leder baserat på medicinteknisk bildbehandling.
Episurf Medical har en mjukvara baserad på artificiell intelligens (AI), vilken genererar 3D-modeller (segmentering) av ledstrukturer. Mjukvaran har utvecklats de senaste åren för att appliceras på olika delar av Episurf Medicals produktionsprocesser. Bolaget slutför nu träning av AI-baserad MR-segmentering för användning för design av bolagets knäimplantat Episealer®. Under våren kommer denna segmenteringsmjukvara att introduceras som en del av knäteknologin Episealer® på den europeiska marknaden och därmed användas i Episurfs produktionsprocess.
”Unikt för oss är att vi kan göra detta baserat på bilder från magnetkameror (MR). Att göra detta baserat på datortomografi är betydligt enklare. Med MR kan man identifiera mjukdelar och vi kan därför göra 3D-modeller av leder där ben och brosk automatiskt identifieras. Tidigare har vi använt en extern segmenteringsservice för knäimplantaten Episealer®, men nu flyttar vi detta inhouse. AI gör automatisk segmentering på bara några minuter och detta gör vår produktionsprocess mycket effektivare. Tidigare tog denna process, allt som allt, flera dagar i anspråk. Jag är mycket imponerad av kraften i AI, och det är mycket spännande att börja använda AI i vårt dagliga arbete.” säger Pål Ryfors, vd Episurf Medical.
Dette bør vel ha verdi for andre bruksområder også?
Kommentar fra Redeye
We argue that this is very exciting news; it strengthens the Episealer Knee offer and ultimately leading to higher gross margins. In our model, we forecast a gross margin potential of around 75 percent. The introduction of AI in the production process is a milestone in that regard.
Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer implant technology will be presented at the 11[th] Symposium Sport Medizin und Mee(h)r, on February 7 - 9 in Kiel, Germany. Dr. med. A. Losch from MedBaltic, Kiel, will hold the presentation with the title Patient-specific partial joint replacement and sports ability.
We are excited over the fact that the European Episealer users are continuing to present and discuss their experiences from using the Episealer knee implant says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Episurf Medical (Nasdaq: EPIS B) today announces that the companys knee implant technology and clinical results will be presented at the 6[th] Annual Meeting of the UK Biological Knee Society, on January 30-31 in Cambridge, the United Kingdom. M.D. Ph.D. M. Högström at Sports Medicine Umeå, Sweden, has been invited to the meeting to give the presentation Metal Mini Prosthesis for Focal Chondral Lesions. The presentation is based on the clinical results from a European multicenter study with 100 patients in the gap age, 35-60 years old, that have undergone treatment of focal chondral defects using the knee implant Episealer.
A large multicentre study of the Episealer implant is ongoing in six European countries, and we are very happy for the fact that clinical results from this study will be presented at this important meeting says Pål Ryfors, CEO Episurf Medical.
Hadde håpet at de snart kunne komme noe nytt mtp finansieringen fremover. Eventuelt fremgang i USA. Tør ikke gå inn igjen før dette er avklart… 
Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent, entitled System and method for creating a decision support material indicating damage to an anatomical joint, is within the area of 3D-based assessment of joint lesions, and complements the companys previously approved patents within that field.
Our visualisation of joint damage, which includes AI-based 3D-modelling, is unique and we are happy to be able to build a strong patent protection around it, says Katarina Flodström, COO, Episurf Medical.
Episurf Medical (NASDAQ: EPIS B) today announces that the companys ankle implant Episealer Talus, recently CE approved, is now additionally approved for sale in Italy and Spain. Notifications to applicable authorities have been completed through National Health Information System (NSIS) Database in Italy and CCPS (Comunicaciones de Productos Sanitaros) in Spain, which fulfils the regulatory requirements for distribution in the corresponding countries. Episealer Talus is further undergoing registration in the Medical Device Registration portal Infarmed in Portugal and that registration is expected to be finalised shortly.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
2020 has started very well and up to the reporting date, the orderbook has increased by 116%. We are currently experiencing rapid growth, and I am happy to conclude that the year has started so well.
2020 is an incredibly important year for us. We are focusing on clinical results in Europe, the surgeries in the EPIC Knee study, strong growth in Europe and the launch of the ankle implant. In our opinion, all of this creates the basis for a very exciting 2020. says Pål Ryfors, CEO Episurf Medical.
Fourth quarter 2019 compared to 2018, Group
Group net sales increased by 18.1% to SEK 1.3m (1.1)
Gross order intake amounted to SEK 1.2m (1.5)
Order backlog amounted to SEK 1.1m (1.2)
21.6% decrease in orders for Episealer knee implants during the quarter with 47 (60) approved orders, the growth during 2020 up to the reporting date amounts to 115.8%.
Loss for the period amounted to SEK -18.7m (-15.3), the increased costs during the quarter are due to the groups work on the IDE study in the US
Earnings per share amounted to SEK -0.21 (-0.49)
Twelve months 2019, compared to twelve months 2018, Group
Gross order intake amounted to SEK 5.0m (4.4) an increase of 15.4%
22.4% increase in orders for Episealer knee implants during the financial year with 202 (165) approved orders
Group net sales increased by 23.5% to SEK 4.9m (4.0)
Loss for the period amounted to SEK -69.8m (-57.8), the increased costs during the twelve months are due to the groups work on the IDE study in the US
Earnings per share amounted to SEK -1.04 (-1.71)
Significant events during the fourth quarter
Dr. Kevin D. Plancher was appointed Lead Investigator for Episurfs Episealer IDE study
US, Chinese, European and UK patent approvals for Episurf Medical
Episurf Medical signed Italian distributor agreement
Clinical data were presented in the UK, Germany, Italy and the US
Clinical results for Episealer were accepted as poster presentation for the ESSKA Congress
Significant events after the fourth quarter
Episurf Medical received CE mark for Episealer Talus and Talus Osteotomy Guide
Episurf Medical updated on AI-based production process
Episealer will be presented at sports medicine meeting in Germany
Clinical data for Episealer were presented at orthopaedic congress in The United Kingdom
US patent approval for Episurf Medical
Episealer Talus was registered for sale in Italy and Spain
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical